The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Intermittent Trimethoprim-Sulfamethoxazole Compared with Dapsone-Pyrimethamine for the Simultaneous Primary Prophylaxis of Pneumocystis Pneumonia and Toxoplasmosis in Patients Infected with HIV

Daniel Podzamczer, MD; Albert Salazar, MD; Josep Jimenez, MD; Ezequiel Consiglio, MD; Miguel Santin, MD; Aurora Casanova, MD; Gabriel Rufi, MD; and Francisco Gudiol, MD
[+] Article, Author, and Disclosure Information

From Ciutat Sanitaria de Bellvitge, University of Barcelona, Barcelona, Spain. Requests for Reprints: Daniel Podzamczer, MD, Infectious Disease Service, Ciutat Sanitaria de Bellvitge, c/Feixa Llarga s/n, L'Hospitalet, 08907 Barcelona, Spain. Grant Support: In part by grant FISS 91/0469 from the Fondo de Investigacion de la Seguridad Social.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1995;122(10):755-761. doi:10.7326/0003-4819-122-10-199505150-00004
Text Size: A A A

Objective: To evaluate the efficacy and safety of two oral, intermittent drug regimens for the simultaneous primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with HIV infection.

Design: Nonblinded randomized study: Patients received either 1) trimethoprim-sulfamethoxazole [160 mg-800 mg orally twice a day on a thrice weekly regimen] or 2) 100 mg of dapsone plus 50 mg of pyrimethamine orally twice weekly.

Setting: University teaching hospital in Barcelona.

Patients: 230 patients infected with HIV who had CD4 cell counts of less than 200 × 106/L and who had not previously had P. carinii pneumonia or toxoplasmosis.

Measurements: Clinical and biological evaluations; adverse reactions; and end points of P. carinii pneumonia, toxoplasmosis, and death.

Results: After a median follow-up of 430 days, 6 (6.3%) of 96 evaluable patients receiving dapsone-pyrimethamine and 0 of 104 evaluable patients receiving trimethoprim-sulfamethoxazole developed P. carinii pneumonia (P < 0.0001). The cumulative rates of P. carinii pneumonia at 12 and 24 months were 0% and 0% for patients receiving trimethoprim-sulfamethoxazole and 4% and 11% for patients receiving dapsone-pyrimethamine (Mantel-Cox, P = 0.014). However, only one episode of P. carinii pneumonia developed while patients were taking these drugs. No differences were observed for toxoplasmosis (one episode in the trimethoprim-sulfamethoxazole arm and two in the dapsone-pyrimethamine arm), with cumulative rates at 12 and 24 months of 0% and 4% for the trimethoprim-sulfamethoxazole arm and 2% and 7% for the dapsone-pyrimethamine arm (P = 0.65). Similar mortality rates were observed during follow-up (P = 0.85). Nineteen patients (9.5%) discontinued therapy with the drugs because of adverse effects: Ten were in the trimethoprim-sulfamethoxazole arm and 9 were in the dapsone-pyrimethamine arm (P = 0.95).

Conclusions: Thrice-weekly trimethoprim-sulfamethoxazole is an effective and well-tolerated regimen for the simultaneous primary prophylaxis of P. carinii pneumonia and toxoplasmosis in patients infected with HIV. Twice-weekly dapsone-pyrimethamine appears to be a safe and effective alternative.


Grahic Jump Location
Figure 1.
Cumulative rates of Pneumocystis carinii pneumonia according to prophylaxis regimen (Kaplan-Meier product-limit estimates).Pneumocystis carinii

DP = dapsone-pyrimethamine; PCP = pneumonia; TMP-SMX = trimethoprim-sulfamethoxazole (cotrimoxazole).

Grahic Jump Location
Grahic Jump Location
Figure 2.
Cumulative rates of toxoplasmosis in patients seropositive for Toxoplasma gondii according to prophylaxis regimen.

(Kaplan-Meier product-limit estimates). DP = dapsone-pyrimethamine; TMP-SMX = trimethoprim-sulfamethoxazole (co-trimoxazole).

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.